In the last trading session, 1.03 million Iterum Therapeutics Plc (NASDAQ:ITRM) shares changed hands as the company’s beta touched 2.76. With the company’s per share price at $0.95 changed hands at -$0.05 or -4.46% during last session, the market valuation stood at $38.08M. ITRM’s last price was a discount, traded about -217.89% off its 52-week high of $3.02. The share price had its 52-week low at $0.81, which suggests the last value was 14.74% up since then.

Analysts gave the Iterum Therapeutics Plc (ITRM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ITRM as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.

Iterum Therapeutics Plc (NASDAQ:ITRM) trade information

Instantly ITRM was in red as seen at the end of in last trading. With action 1.47%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -46.20%, with the 5-day performance at 1.47% in the green. However, in the 30-day time frame, Iterum Therapeutics Plc (NASDAQ:ITRM) is -7.55% down.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 29.27%. The 2025 estimates are for Iterum Therapeutics Plc earnings to increase by 57.87%, but the outlook for the next 5-year period is at 55.20% per year.

ITRM Dividends

Iterum Therapeutics Plc is expected to release its next quarterly earnings report in June.

ANCORA ADVISORS, LLC holds the second largest percentage of outstanding shares.